PE20230258A1 - Formulaciones liquidas de analogos de glucagon - Google Patents

Formulaciones liquidas de analogos de glucagon

Info

Publication number
PE20230258A1
PE20230258A1 PE2022001968A PE2022001968A PE20230258A1 PE 20230258 A1 PE20230258 A1 PE 20230258A1 PE 2022001968 A PE2022001968 A PE 2022001968A PE 2022001968 A PE2022001968 A PE 2022001968A PE 20230258 A1 PE20230258 A1 PE 20230258A1
Authority
PE
Peru
Prior art keywords
glucagon analogues
liquid formulations
formulations
single dose
relates
Prior art date
Application number
PE2022001968A
Other languages
English (en)
Inventor
Jesper Skodborg VILLADSEN
Bøving Tine Elisabeth Gottschalk
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of PE20230258A1 publication Critical patent/PE20230258A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Abstract

La presente invencion se refiere a formulaciones de analogos de glucagon, o una sal farmaceuticamente aceptable del mismo y/o un derivado del mismo; y su uso medico, por ejemplo, en el tratamiento de la hipoglucemia. En particular, la presente invencion se refiere a formulaciones liquidas acuosas estables de analogos de glucagon que comprenden combinaciones de excipientes que los hacen adecuados para el almacenamiento a largo plazo como liquidos, y pueden ser usados en formulaciones de dosis unica (SD) o de dosis multiples (MD).
PE2022001968A 2020-03-16 2021-03-16 Formulaciones liquidas de analogos de glucagon PE20230258A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20163408 2020-03-16
PCT/EP2021/056651 WO2021185821A1 (en) 2020-03-16 2021-03-16 Liquid formulations of glucagon analogues

Publications (1)

Publication Number Publication Date
PE20230258A1 true PE20230258A1 (es) 2023-02-07

Family

ID=70008261

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001968A PE20230258A1 (es) 2020-03-16 2021-03-16 Formulaciones liquidas de analogos de glucagon

Country Status (16)

Country Link
US (1) US20210283053A1 (es)
EP (1) EP4121003A1 (es)
JP (1) JP2023518052A (es)
KR (1) KR20220154110A (es)
CN (1) CN115279341A (es)
AR (1) AR121581A1 (es)
AU (1) AU2021236878A1 (es)
BR (1) BR112022018462A2 (es)
CA (1) CA3171184A1 (es)
CL (1) CL2022002472A1 (es)
CO (1) CO2022014452A2 (es)
IL (1) IL295977A (es)
MX (1) MX2022011227A (es)
PE (1) PE20230258A1 (es)
TW (1) TW202200190A (es)
WO (1) WO2021185821A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CN102933598A (zh) 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
HUE049413T2 (hu) 2015-02-17 2020-09-28 Lilly Co Eli Nazális porkészítmény hipoglikémia kezelésére
WO2017053822A1 (en) 2015-09-23 2017-03-30 Behavioral Recognition Systems, Inc. Detected object tracker for a video analytics system
GB201710822D0 (en) * 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia
US20190275110A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid

Also Published As

Publication number Publication date
CA3171184A1 (en) 2021-09-23
AU2021236878A1 (en) 2022-09-29
CL2022002472A1 (es) 2023-02-17
US20210283053A1 (en) 2021-09-16
EP4121003A1 (en) 2023-01-25
IL295977A (en) 2022-10-01
JP2023518052A (ja) 2023-04-27
KR20220154110A (ko) 2022-11-21
BR112022018462A2 (pt) 2022-11-01
AR121581A1 (es) 2022-06-15
CO2022014452A2 (es) 2022-10-21
TW202200190A (zh) 2022-01-01
WO2021185821A1 (en) 2021-09-23
CN115279341A (zh) 2022-11-01
MX2022011227A (es) 2022-10-07

Similar Documents

Publication Publication Date Title
CO2020001743A2 (es) Métodos de tratamiento para la fibrosis quística
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
CO6220962A2 (es) Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina
ECSP19018654A (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso
CL2019003660A1 (es) Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2).
CL2021000678A1 (es) Formulaciones de análogos del péptido similar a glucagón tipo 2 (glp-2)
CR20170293A (es) Derivados de glucagón con estabilidad mejorada
AR110301A1 (es) Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
ECSP21023398A (es) Dosis unitaria de vacuna contra el dengue y administración de esta
CL2017001186A1 (es) Comprimido multicapa que contiene un fármaco inestable a la luz
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
CO2018011063A2 (es) Métodos de tratamiento con vitamina d
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CO2023015528A2 (es) Estimuladores de guanilil ciclasa soluble (sgc)
NI201000181A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona.
PE20230258A1 (es) Formulaciones liquidas de analogos de glucagon
UY37555A (es) Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
CO2023005726A2 (es) Formulación sólida
CO2022014960A2 (es) Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
CO2022000211A2 (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
CL2016001952A1 (es) Formulación farmacéutica tópica que comprende 50 a 2.500 ui/ml de sal de heparina, menos de o igual a 30% v/v de agua, 0% a 30% v/v de un alcohol de cadena inferior; y no menos de 45% v/v de un vehículo miscible en agua seleccionado del grupo que comprende propilenglicol, glicerol, glicofurol, polietilenglicol, o sus mezclas, util en tromboflebitis venosa superficial.
AR103267A1 (es) Método para preparación de liposomas que contienen un ingrediente farmacéutico activo
CL2014003326A1 (es) Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene.